ENDRA Life Sciences Reports Exit/Disposal Activities in 8-K

TL;DR

**ENDRA Life Sciences is making big changes, expect some costs now for potential gains later.**

AI Summary

ENDRA Life Sciences Inc. filed an 8-K on March 25, 2026, reporting activities related to Item 2.05 (Costs Associated with Exit or Disposal Activities) and Item 7.01 (Regulation FD Disclosure), with a period of report of March 19, 2026. This indicates the company is undergoing significant restructuring or asset divestment, which could impact future operational costs and revenue streams. For investors, this matters because such activities often signal a strategic shift, potentially leading to short-term expenses but aiming for long-term efficiency or focus, which could affect stock valuation.

Why It Matters

This filing signals that ENDRA Life Sciences is likely restructuring or divesting assets, which could lead to one-time costs but potentially improve future financial health and focus.

Risk Assessment

Risk Level: medium — Exit or disposal activities can be costly and disruptive in the short term, introducing uncertainty about the company's immediate financial performance.

Analyst Insight

A smart investor would monitor subsequent filings for details on the 'exit or disposal activities' to understand the scope and potential financial impact, as these could be short-term negatives for long-term strategic benefits.

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — the filer of the 8-K
• March 25, 2026 (date) — the filing date of the 8-K
• March 19, 2026 (date) — the period of report for the 8-K
• 0001681682 (company) — CIK of ENDRA Life Sciences Inc.

Forward-Looking Statements

• ENDRA Life Sciences will announce specific details of its exit or disposal activities. (ENDRA Life Sciences Inc.) — medium confidence, target: 2026-06-25
• The company's financial statements will reflect one-time costs associated with these activities. (ENDRA Life Sciences Inc.) — high confidence, target: 2026-09-30

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
• $51,000 — r pre-tax cash charges of approximately $51,000 associated with severance payments to f

Filing Documents

• ea0283331-8k_endra.htm (8-K) — 25KB
• ea028333101ex99-1.htm (EX-99.1) — 10KB
• 0001213900-26-033878.txt ( ) — 200KB
• ndra-20260319.xsd (EX-101.SCH) — 3KB
• ndra-20260319_lab.xml (EX-101.LAB) — 33KB
• ndra-20260319_pre.xml (EX-101.PRE) — 22KB
• ea0283331-8k_endra_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On March 25, 2026, ENDRA Life Sciences Inc. (the "Company") announced that it has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. In connection with this revised strategy, on March 19, 2026, the Company reduced the number of its employees in order to reduce cash expenditures and extend its operational runway. As a result, the Company expects to incur pre-tax cash charges of approximately $51,000 associated with severance payments to former employees. While the Company will continue to pursue its TAEUS business, this charge reflects the change in strategic direction for the Company. The Company expects to recognize the severance charges in the first quarter of 2026.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On March 25, 2026, the Company issued a press release announcing that it has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Number Description 99.1 Press Release dated March 25, 2026, furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. March 25, 2026 By: /s/ Alexander Tokman Name: Alexander Tokman Title: Chief Executive Officer and Chairman 2

View Full Filing

View this 8-K filing on SEC EDGAR